Prostate Cancer Foundation Announces New Recipients of 2016 PCF Challenge Awards to Promote Research in Deadly Prostate Cancer

SANTA MONICA, CA Feb. 14, 2017 – The Prostate Cancer Foundation (PCF) today announced that it has granted eight new 2016 PCF Challenge Awards to advance treatments and cures for metastatic or currently incurable prostate cancer.  PCF Challenge Awards are multi-year awards supporting cross-disciplinary teams of research scientists.  In 2016,.


Genetic Counseling Center Dedicated To Advanced Prostate Cancer Opens In Seattle

Prostate cancer is one of the most heritable forms of cancer. Hereditary mutations in “DNA repair” genes – BRCA1, BRCA2, and others – which are best known for their association with breast and ovarian cancer predisposition, are now known to be associated with advanced prostate cancer. In fact, ~12% of.


The Prostate Cancer Foundation’s 2016 Coffey-Holden Prostate Cancer Academy Meeting Accelerates Advances In The Understanding And Treatment Of Metastatic Prostate Cancer

The Prostate Cancer Foundation (PCF) has a legacy of not only funding the most impactful research in prostate cancer, but also creating new infrastructures, global knowledge networks, and research initiatives that support and accelerate prostate cancer research towards better treatment for advanced prostate cancer patients. For the past four years,.


New study finds one in nine men with metastatic prostate cancer carry inherited mutations in DNA repair genes with important implications for treatment and for cancer risk in family members

https://www.youtube.com/embed/8pjv5M7G58U Cancer, the uncontrolled growth of cells, is caused by the acquisition of genetic mutations that allow cells to evade the normal biological laws governing when and where they can grow in the body. Mechanisms that maintain the accuracy of our genomes are critical for preventing cells from collecting mutations.


New Clinical Trial Endpoint May Speed The Development Of New Therapies For Patients With Localized Prostate Cancer

At the 2016 American Society of Clinical Oncology (ASCO) Annual Conference, Dr. Christopher Sweeney presented results from ICECaP (Intermediate Clinical Endpoints in Cancer of the Prostate), a Prostate Cancer Foundation (PCF)-supported initiative, that will halve the time required to assess new therapies for aggressive prostate cancer. "We need to move.


Obesity And A High-fat Diet Promote Prostate Cancer Progression By Amplifying The Activity Of Cancer Genes

At the 2016 Annual American Association for Cancer Research (AACR) Conference, Giorgia Zadra, PhD, of the Harvard: Dana-Farber Cancer Institute and Brigham and Women's Hospital, presented results from a study that helped to clarify the relationship between obesity and prostate cancer. The skinny? Fat increases the activity of a critical.


Inherited Defects In Breast And Ovarian Cancer Genes Predispose To Prostate Cancer With Worse Outcomes

At the 2016 American Association for Cancer Research (AACR) Annual Meeting, Dr. Joaquin Mateo, a medical oncologist at the Institute for Cancer Research, UK, presented results from a new study which assessed hormone therapy-resistant prostate cancer patients for the prevalence of hereditary alterations in DNA repair genes. An estimated 50-60%.


New Genetic Test Helps To Select Best Medicines For Prostate Cancer Treatment And Identifies Hereditary Cancer Genes

Like self-driving cars, precision medicine for prostate cancer is no promise of the distant future -- with the efforts of Prostate Cancer Foundation (PCF)-funded researchers and others, the prototypes have arrived. The first major precision medicine studies were huge -- utilizing "whole exome" sequencing, in which every gene expressed by.



What this means for patients: Obesity is a known risk factor for prostate cancer, but the reasons for this remain unknown. This study identifies expression of chromatin remodeling genes as a likely mechanism linking these processes, and may lead to the development of therapies for obesity-related prostate cancer. June 2,.


The PARP-inhibitor Olaparib may be the first precision medicine therapy to reach prostate cancer patients

What this means for patients: A Phase II clinical trial found that up to one-third of metastatic prostate cancer patients have mutations in genes that control DNA repair in their tumors, causing them to selectively respond to treatment with olaparib. This therapy was recently approved for ovarian cancer patients who.